| 1 |
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
|
|
Dubois, Bruno; Hampel, Harald; Feldman, Howard H; Scheltens, Philip; Aisen, Paul; Andrieu, Sandrine; Bakardjian, Hovagim; Benali, Habib; Bertram, Lars; Blennow, Kaj; Broich, Karl; Cavedo, Enrica; Crutch, Sebastian; Dartigues, Jean-François; Duyckaerts, Charles; Epelbaum, Stéphane; Frisoni, Giovanni B; Gauthier, Serge; Genthon, Remy; Gouw, Alida A; Habert, Marie-Odile; Holtzman, David M; Kivipelto, Miia; Lista, Simone; Molinuevo, José-Luis; O'Bryant, Sid E; Rabinovici, Gil D; Rowe, Christopher; Salloway, Stephen; Schneider, Lon S; Sperling, Reisa; Teichmann, Marc; Carrillo, Maria C; Cummings, Jeffrey; Jack, Cliff R; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA
|
|
In: Alzheimer's & dementia : the journal of the Alzheimer's Association, vol 12, iss 3 (2016)
|
|
Abstract:
During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.
|
|
Keyword:
2015; Acquired Cognitive Impairment; Aging; Alzheimer Disease; Alzheimer's disease; Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD); Amyloid PET; Animals; Asymptomatic; Biomarkers; Blood biomarkers; Brain; Brain Disorders; Clinical Sciences; CSF biomarkers; Dementia; Diagnostic criteria; Disease Progression; Genetics; Geriatrics; Human Genome; Humans; July 23; MRI; Neurodegenerative; Neurological; Neurosciences; Pathophysiology; Preclinical; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclinical State of AD”; Tau PET; USA; Washington DC
|
|
URL: https://escholarship.org/uc/item/3cn0w6q0
|
|
BASE
|
|
Hide details
|
|
|
| 2 |
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
|
|
|
|
In: Alzheimer's & dementia : the journal of the Alzheimer's Association, vol 12, iss 3 (2016)
|
|
BASE
|
|
Show details
|
|
|
| 3 |
Therapy and clinical trials in frontotemporal dementia: past, present, and future.
|
|
|
|
In: Journal of neurochemistry, vol 138 Suppl 1, iss S1 (2016)
|
|
BASE
|
|
Show details
|
|
|
| 4 |
Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts: Completing the picture.
|
|
|
|
In: Neurology(R) neuroimmunology & neuroinflammation, vol 3, iss 6 (2016)
|
|
BASE
|
|
Show details
|
|
|
| 5 |
Neuroeconomic dissociation of semantic dementia and behavioural variant frontotemporal dementia.
|
|
|
|
In: Brain : a journal of neurology, vol 139, iss Pt 2 (2016)
|
|
BASE
|
|
Show details
|
|
|
|
|
